This author has yet to write their bio.Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 178 entries.
Botanix Pharmaceutical’s ground-breaking research on the antimicrobial potential of cannabidiol (CBD) has been published by a leading South American academic group in BioRxiv. The BioRxiv article confirms our discovery that synthetic CBD can also kill a select group of Gram-negative bacteria, including the bacteria responsible for the sexually transmitted disease gonorrhoea and the increasingly challenging […]
Senior writer for Freethink, B.David Zarley, has published a feature article titled ‘Can CBD be the Next Superbug Slayer?’ It examines the importance Botanix’s research into the antimicrobial potential of cannabidiol and includes comments from Dr Mark Blaskovich, Director of UQ’s IMB Centre for Superbug Solutions and collaborator on our BTX 1801 antimicrobial research. Read […]
Addressing the pressing global emergency of antimicrobial resistance (AMR) is central to our work at Botanix Pharmaceuticals (ASX:BOT). Our BTX 1801 antimicrobial platform program is designed to offer novel treatments and solutions, leveraging the unique power of synthetic CBD. This week, the ABC in Australia aired the final episode of its three-part Invisible Wars documentary […]
Australian medicinal cannabis revenue is tipped to double this year amid growing confidence in the emerging sector. And WA is poised to maintain a significant hold of the market share. While the State is recognised globally for its optimal growing conditions, local cultivators, manufacturers and researchers have also benefited from limited COVID-19 interference in their […]
Papulopustular rosacea is a highly visible and distressing chronic inflammatory skin disease characterised by intensely inflamed skin and acne-like breakouts across the face – and new therapies are in demand. Botanix has today announced that we have received ethics approval for our BTX 1702 Phase 1b clinical study for the treatment of papulopustular rosacea, together […]
The Australian Government has published the Final Progress Report for Australia’s First National Antimicrobial Resistance Strategy 2015–2019 detailing its efforts to limit the incidence of antimicrobial resistance (AMR) in Australia. The report highlights activities implemented between 2017 and 2019 in the human and animal health, food production and the environment. Looking ahead, the Australian Government […]
Botanix Pharmaceuticals President and Executive Chairman, Vince Ippolito, presented at the ASX Small and Mid-Cap Conference today. View the presentation here:
Article extract | “Novartis’ acquisition represents a double-down on an antibiotics field facing an existential crisis from resistant “super bugs” that have sent most major drugmakers running for the hills — including Novartis, which dumped its antibiotic R&D program in 2018. But adding ever-greater volume to their generic antibiotics portfolio could offer Novartis some bottom-line […]
‘A huge acquisition in the international medical cannabis sector is set to give tailwinds to several ASX-listed marijuana companies, Scott Power says. Ireland-based Jazz Pharmaceuticals (NASDAQ:JAZZ) this week agreed to buy cannabinoid drugmaker GW Pharmaceuticals (NASDAQ:GWPH) for $US7.2 billion ($9.4 billion) – a 50 per cent premium to GW’s closing price on Tuesday.’ Click through to read the full article […]
GW Pharma $GWPH, the UK biotech that caused a sensation of sorts with the approval of the world’s first cannabinoid med, is being bought out. Jazz Pharmaceuticals came up with the winning number, agreeing to acquire GW for a total of $7.2 billion — $6.7 billion net of cash. GW agreed to a price of […]
